Impact of neutralizing antibodies on the clinical efficacy of interferon beta in multiple sclerosis

Journal of Neurology, Supplement

Volumn 251, Issue 2, 2004, Pages

  Vartanian, Timothy ^a   Sørensen, Per Sölberg ^b   Rice, George ^c  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b Rigshospitalet   (Denmark)

^c UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

Immunogenicity; Interferon beta; Multiple sclerosis; Neutralizing antibodies; Protein therapeutics

Indexed keywords

BETA1A INTERFERON; INTERFERON BETA SERINE; NEUTRALIZING ANTIBODY;

CLINICAL TRIAL; CONFERENCE PAPER; DISEASE ACTIVITY; DISEASE COURSE; DRUG EFFICACY; HUMAN; IMMUNOGENICITY; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL;

ADJUVANTS, IMMUNOLOGIC; ANTIBODIES; ANTIBODY SPECIFICITY; CLINICAL TRIALS, PHASE III; DISABILITY EVALUATION; EVIDENCE-BASED MEDICINE; HUMANS; INTERFERON-BETA; MULTIPLE SCLEROSIS; TIME FACTORS;

EID: 3242885605     PISSN: 09391517     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (22)

1. Berman E, Heller G, Kempin S, Gee T, Tran LL, Clarkson B (1990) Incidence of response and long-term follow-up in a patient with hairy cell leukemia treated with recombinant interferon alfa-2a. Blood 75:839-845
2. Fineberg SE, Galloway JA, Fineberg NS, Rathbun MJ, Hufferd S (1983) Immunogenicity of recombinant DNA human insulin. Diabetologia 25:465-469
3. Freund M, von Wussow P, Diedrich H, Eisert R, Link H, Wilke H, Buchholz F, LeBlanc S, Fonatsch C, Deicher H, Poliwoda H (1989) Recombinant human interferon (IFN) alpha-2b in chronic myelogenous leukemia: dose dependency of response and frequency of neutralizing anti-interferon antibodies. Br J Haematol 72:350-356
4. The IFNB Multiple Sclerosis Study Group (1993) Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 43:655-661
5. The IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group (1996) Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-1b: Experience during the first three years. Neurology 47:889-894
6. Jacobs LD, Cookfair DL, Rudick RA, Herndon RM, Richert JR, Salazar AM, Fischer JS, Goodkin DE, Granger CV, Simon JH, Alam JJ, Bartoszak DM, Bourdette DN, Braiman J, Brownscheidle CM, Coats ME, Cohan SL, Dougherty DS, Kinkel RP, Mass MK, Munschauer FE, III, Priore RL, Pullicino PM, Scherokman BJ, Weinstock-Guttman B, Whitham RH, and The Multiple Sclerosis Collaborative Research Group (MSCRG) (1996) Intramuscular Interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 39:285-294
7. Leroy V, Baud M, de Traversay C, Maynard-Muet M, Lebon P, Zarski JP (1998) Role of anti-interferon antibodies in breakthrough occurrence during alpha 2a and 2b therapy in patients with chronic hepatitis C. J Hepatol 28:375-381
8. Lusher JM (2000) Factor VIII inhibitors with recombinant products: prospective clinical trials. Haematologica 85:2-6
9. Meager A (1994) Human antibodies to insulin in diabetes. J Interferon Res 14:181-182
10. Oberg K, Alm G, Magnusson A, Lundqvist G, Theodorsson E, Wide L, Wilander E (1989) Treatment of malignant carcinoid tumors with recombinant interferon alfa-2b: development of neutralizing interferon antibodies and possible loss of antitumor activity. J Natl Cancer Inst 81:531-535
11. Panitch H, Goodin DS, Francis G, Chang P, Coyle PK, O'Connor P, Monaghan E, Li D, Weinshenker B, for the EVIDENCE (Evidence of Interferon Dose-response: European North American Comparative Efficacy) Study Group and the University of British Columbia MS/MRI Research Group (2002) Randomized, comparative study of interferon β-1a treatment regimens in MS. The EVIDENCE Trial. Neurology 59:1496-1506
12. Polman C, Kappos L, White R, Dahlke F, Beckmann K, Pozzilli C, Thompson A, Petkau I, Miller D, for the European Study Group in Interferon β-1b in Secondary Progressive MS (2003) Neutralizing antibodies during treatment of secondary progressive MS with interferon β-1b. Neurology 60:37-43
13. PRISMS (Prevention of Relapses and Disability by Interferon β-1a Subcutaneously in Multiple Sclerosis) Study Group (1998) Randomised double-blind placebo-controlled study of interferon β-1 a in relapsing/remitting multiple sclerosis. Lancet 352:1498-1504
14. The PRISMS (Prevention of Relapses and Disability by Interferon-β-1a Subcutaneously in Multiple Sclerosis) Study Group and the University of British Columbia MS/MRI Analysis Group (2001) PRISMS-4: Long-term efficacy of interferon-β-1a in relapsing MS. Neurology 56:1628-1636
15. Quesada JR, Itri L, Gutterman JU (1987) Alpha interferons in hairy cell leukemia (HCL). A five year follow up in 100 patients. J Interferon Res 7:678
16. Quesada JR, Rios A, Swanson D, Trown P, Gutterman JU (1985) Antitumor activity of recombinant-derived interferon alpha in metastatic renal cell carcinoma. J Clin Oncol 3:1522-1528
17. Rice GPA, Francis GS, and the PRISMS Study Group (2001) Further evidence of dose effect of IFN beta-1 a based on neutralizing antibody status. Poster presented at the 11th Annual Meeting of the European Neurological Society; April 21-25, 2001; Paris, France
18. Rudick RA, Simonian NA, Alam JA, Campion M, Scaramucci JO, Jones W, Coats ME, Goodkin DE, Weinstock-Guttman B, Herndon RM, Mass MK, Richert JR, Salazar AM, Munschauer FE III, Cookfair DL, Simon JH, Jacobs LD, and the Multiple Sclerosis Collaborative Research Group (MSCRG) (1998) Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis. Neurology 50:1266-1272
19. Schellekens H (2002) Bioequivalence and the immunogenicity of biopharmaceuticals. Nat Rev 1:457-462
20. Sorensen PS, Ross C, Clemmesen KM, et al., and the Danish Multiple Sclerosis Study Group (2003) Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis. Lancet 2003; 362:1184-1191
21. Steis RG, Smith JW II, Urba WJ, Clark JW, Itri LM, Evans LM, Schoenberger C, Longo DL (1988) Resistance to recombinant interferon alfa-2a in hairy-cell leukemia associated with neutralizing anti-interferon antibodies. N Engl J Med 318:1409-1413
22. von Wussow P, Freund M, Block B, Diedrich H, Poliwoda H, Deicher H (1987) Clinical significance of anti-IFN-α antibody titres during interferon therapy. Lancet 2:635-636